- Home
- ICCM vs BAFN Comparison
ICCM vs BAFN Comparison
Compare ICCM & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- BAFN
- Stock Information
- Founded
- ICCM 2006
- BAFN 1999
- Country
- ICCM Israel
- BAFN United States
- Employees
- ICCM N/A
- BAFN N/A
- Industry
- ICCM
- BAFN Savings Institutions
- Sector
- ICCM
- BAFN Finance
- Exchange
- ICCM Nasdaq
- BAFN Nasdaq
- Market Cap
- ICCM 74.7M
- BAFN 70.2M
- IPO Year
- ICCM N/A
- BAFN N/A
- Fundamental
- Price
- ICCM $1.11
- BAFN $18.15
- Analyst Decision
- ICCM Strong Buy
- BAFN
- Analyst Count
- ICCM 1
- BAFN 0
- Target Price
- ICCM $2.50
- BAFN N/A
- AVG Volume (30 Days)
- ICCM 352.8K
- BAFN 9.3K
- Earning Date
- ICCM 03-27-2025
- BAFN 04-24-2025
- Dividend Yield
- ICCM N/A
- BAFN 1.76%
- EPS Growth
- ICCM N/A
- BAFN 134.19
- EPS
- ICCM N/A
- BAFN 2.62
- Revenue
- ICCM $3,291,000.00
- BAFN $83,769,000.00
- Revenue This Year
- ICCM $75.63
- BAFN N/A
- Revenue Next Year
- ICCM $69.36
- BAFN N/A
- P/E Ratio
- ICCM N/A
- BAFN $7.14
- Revenue Growth
- ICCM 1.92
- BAFN 10.60
- 52 Week Low
- ICCM $0.48
- BAFN $10.40
- 52 Week High
- ICCM $1.66
- BAFN $19.75
- Technical
- Relative Strength Index (RSI)
- ICCM 35.03
- BAFN 49.47
- Support Level
- ICCM $1.04
- BAFN $17.13
- Resistance Level
- ICCM $1.25
- BAFN $19.00
- Average True Range (ATR)
- ICCM 0.09
- BAFN 0.83
- MACD
- ICCM -0.04
- BAFN -0.12
- Stochastic Oscillator
- ICCM 14.29
- BAFN 39.16
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.